Sirnaomics, Inc., which focuses on the application of nucleic acid interference technology (RNAi) for new drug creation, has completed a series D round of financing of US$105 million (about RMB730 million yuan). This round of financing was jointly led by exisitng shareholder Rotating Boulder Fund, new investment institution Walvax Biotechnology and River Head Capital. Eixisting […]

RNAi New Drug Startup Sirnaomics Raises $105 Million comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.